Lutris Pharma
lutris-pharma.com
Actively hiring
Biotechnology
Oncology Therapeutics
Health Care
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$30M
1 round on record
Latest round
$30M
Venture round · Feb 2025 · 20 mo ago
Backers
2
aMoon, Pontifax
The money's age
Due for its next round
20 months since the last round · not hiring
Momentum
15/100
in the news
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Apr 29, 2025
New executive Lutris Pharma Announces the Appointment of Seasoned Life Science Executive, Sumant Ramachandra, M.D., Ph.D., as Chief Executive Officer · PRNewswire
Feb 3, 2025
Raised a round Venture round $30M · Pulse 2.0
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Feb 2025 | $30M | — | Pulse 2.0 |
Backed byfrom the funds' portfolios and accelerator catalogs
aMoon 
Pontifax Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Alpheus is advancing a new therapeutic approach designed to improve outcomes while reducing treatment burden for patients and families.
Opna Bio is a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics. The…
KAHR Bio: Pioneering Immunotherapeutics for Advanced Cancer Treatment.
Yemaachi is creating the world's most diverse cancer bio-database to develop the next generation of cancer drugs that are effective in…
TwoStep Therapeutics. Developing tumor-targeted therapies with broad applicability across solid tumors.
Pioneering the first oral drug for FSHD and advancing cancer treatment solutions.
News
Lutris Pharma to Present Updated Data from Its Phase 2 Trial of LUT014 Gel for the Treatment of Patients With EGFRI-Induced Acneiform Rash at the EADV Congress
/PRNewswire/ -- Lutris Pharma, a clinical stage biopharmaceutical company focused on improving the quality of life and drug adherence for patients treated with...
Read more
Report
Lutris Pharma to Present Data from Its Phase 2 Trial of LUT014 Gel for the Treatment of Patients With EGFRI-Induced Acneiform Rash at the ESMO Gastrointestinal Cancers Congress 2025
Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing cutaneous dose limiting toxicity, today announced the presentation of results from its double-blind, placebo-controlled phase 2 randomized cli
Read more
Report
Lutris Pharma Announces the Appointment of Seasoned Life Science Executive, Sumant Ramachandra, M.D., Ph.D., as Chief Executive Officer
/PRNewswire/ -- Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing cutaneous dose limiting...
Read more
Report
Lutris Pharma Presents New Data from Its Completed Clinical Trial of LUT014 Gel Demonstrating Efficacy in Treating Acneiform Rash Associated with Use of Anti-EGFR Cancer Therapies at AACR Annual Meeting 2025
/PRNewswire/ -- Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing cutaneous dose limiting...
Read more
Report
Lutris Pharma: $30 Million Funding Raised For Advancing Development Of Anti-Cancer Drug Effectiveness
Lutris Pharma - a clinical-stage biopharmaceutical company focused on improving anti-cancer therapies by reducing cutaneous dose-limiting toxicity - announced that it has secured $30 million in financing to advance the development of LUT014, an innovative
Read more
Report
American Academy of Dermatology: The Future of Skin Aging May Be Found in The Kitchen: 2026 American Academy of Dermatology Annual Meeting to Highlight Latest Advancements in Skin, Hair, and Nails
Denver, Colorado--(Newsfile Corp. - March 27, 2026) - As interest grows in how lifestyle factors can influence people's appearance, dermatologists are taking a closer look at how diet may affect the
Read more
Report
Financials
Total raised
$30M
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2025 | $30M | Details |